Equillium reports positive Phase 1b itolizumab data in lupus nephritis

Equillium, Inc.

Topline data: 16 patients; baseline mean UPCR 4.9 g/g → ~73% reduction; overall response rate 81.3% (CR+PR).
Complete response in 37.5%, partial response in 43.8%; ORR comparable to Phase 3 AURORA1 voclosporin study.
Safety: mostly mild/moderate TEAEs (lymphopenia, peripheral edema); no treatment-related serious AEs; >80% steroid taper.
Data triggers Ono's option to acquire itolizumab; decision expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.